![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Hollis-Eden Files IND for NEUMUNE in the U.S.
Hollis-Eden Files IND for NEUMUNE in the U.S.
May 31, 2005
Hollis-Eden Pharmaceuticals has filed an investigational new drug application with the FDA to begin Phase I clinical trials in human volunteers with NEUMUNE (HE2100) in the U.S.
A similar Phase I clinical trial for NEUMUNE is currently ongoing in the Netherlands. NEUMUNE is being developed for the treatment of acute radiation syndrome (ARS). ARS is a potentially lethal condition caused by high-dose radiation exposure that might result from a nuclear or radiological terrorist attack or from an accident at a nuclear facility.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct